
RTC-30 is an orally active, dual pathway ингибитор of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 15 uM against H1650 lung adenocarcinoma cells.
RTC-30 is an orally active, dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 15 uM against H1650 lung adenocarcinoma cells.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.